Literature DB >> 21906045

Age-related penetrance of hereditary atypical hemolytic uremic syndrome.

Maren Sullivan1, Lisa A Rybicki, Aurelia Winter, Michael M Hoffmann, Stefanie Reiermann, Hannah Linke, Klaus Arbeiter, Ludwig Patzer, Klemens Budde, Bernd Hoppe, Martin Zeier, Karl Lhotta, Andreas Bock, Thorsten Wiech, Ariana Gaspert, Thomas Fehr, Magdalena Woznowski, Gani Berisha, Angelica Malinoc, Oemer-Necmi Goek, Charis Eng, Hartmut P H Neumann.   

Abstract

Hereditary atypical hemolytic uremic syndrome (aHUS), a dramatic disease frequently leading to dialysis, is associated with germline mutations of the CFH, CD46, or CFI genes. After identification of the mutation in an affected aHUS patient, single-site gene testing of relatives is the preventive care perspective. However, clinical data for family counselling are scarce. From the German-Speaking-Countries-aHUS-Registry, 33 index patients with mutations were approached for permission to offer relatives screening for their family-specific mutations and to obtain demographic and clinical data. Mutation screening was performed using direct sequencing. Age-adjusted penetrance of aHUS was calculated for each gene in index cases and in mutation-positive relatives. Sixty-one relatives comprising 41 parents and 20 other relatives were enrolled and mutations detected in 31/61. In total, 40 research participants had germline mutations in CFH, 19 in CD46 and in 6 CFI. Penetrance at age 40 was markedly reduced in mutation-positive relatives compared to index patients overall with 10% versus 67% (P < 0.001); 6% vs. 67% (P < 0.001) in CFH mutation carriers and 21% vs. 70% (P= 0.003) in CD46 mutation carriers. Age-adjusted penetrance for hereditary aHUS is important to understand the disease, and if replicated in the future, for genetic counselling.
© 2011 The Authors Annals of Human Genetics © 2011 Blackwell Publishing Ltd/University College London.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906045     DOI: 10.1111/j.1469-1809.2011.00671.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  15 in total

Review 1.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

2.  Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.

Authors:  Martina Gaggl; Christof Aigner; Dorottya Csuka; Ágnes Szilágyi; Zoltán Prohászka; Renate Kain; Natalja Haninger; Maarten Knechtelsdorfer; Raute Sunder-Plassmann; Gere Sunder-Plassmann; Alice Schmidt
Journal:  J Am Soc Nephrol       Date:  2017-12-27       Impact factor: 10.121

3.  Modified Ham test for atypical hemolytic uremic syndrome.

Authors:  Eleni Gavriilaki; Xuan Yuan; Zhaohui Ye; Alexander J Ambinder; Satish P Shanbhag; Michael B Streiff; Thomas S Kickler; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

Review 4.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

5.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

6.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Authors:  Véronique Fremeaux-Bacchi; Fadi Fakhouri; Arnaud Garnier; Frank Bienaimé; Marie-Agnès Dragon-Durey; Stéphanie Ngo; Bruno Moulin; Aude Servais; François Provot; Lionel Rostaing; Stéphane Burtey; Patrick Niaudet; Georges Deschênes; Yvon Lebranchu; Julien Zuber; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

7.  Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis.

Authors:  James Collett; Amali Mallawaarachchi; Eddy Fischer; Muralikrishna Gangadharan Komala; Kamal Sud; Bhadran Bose
Journal:  Clin Kidney J       Date:  2017-03-02

Review 8.  Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.

Authors:  Fengxiao Bu; Nicolo Borsa; Ardissino Gianluigi; Richard J H Smith
Journal:  Clin Dev Immunol       Date:  2012-11-08

Review 9.  Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Authors:  Edwin K S Wong; Tim H J Goodship; David Kavanagh
Journal:  Mol Immunol       Date:  2013-06-28       Impact factor: 4.174

Review 10.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.